Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 14;41(4):302-307.
doi: 10.3760/cma.j.issn.0253-2727.2020.008.

[Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia]

[Article in Chinese]
Affiliations

[Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia]

[Article in Chinese]
Y Zhang et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract

Objective: To investigate the clinical and coagulation characteristics in patients with critical Coronavirus disease 2019 (COVID-19) and acro-ischemia. Methods: The retrospective study included 7 critical COVID-19 patients with acro-ischemia in an intensive care unit (ICU) in Wuhan, from Feb 4 to Feb 15, 2020. The clinical and laboratory data before and during the ICU stay were analyzed. Results: The median age of 7 patients was 59 years and 4 of them were men. Three patients were associated with underlying comorbidities. Fever, cough, dyspnea and diarrhea were common clinical symptoms. All patients had acro-ischemia presentations including finger/toe cyanosis, skin bulla and dry gangrene. D-dimer, fibrinogen and fibrinogen degradation product (FDP) were significantly elevated in most patients. Prothrombin time was prolonged in 4 patients. D-dimer and FDP levels progressively elevated consistent with COVID-2019 exacerbation. Four patients were diagnosed with disseminated intravascular coagulation (DIC) . Low molecular weight heparin (LMWH) was administrated in 6 patients, which reduced D-dimer and FDP rather than improved clinical symptoms. Five patients died finally and the median time from acro-ischemia to death was 12 days. Conclusions: Coagulation parameters should be monitored closely in critical COVID-2019 patients. The timing and protocol of anticoagulation therapy are still under investigation based on more clinical data.

目的: 总结合并肢端缺血的新型冠状病毒肺炎(COVID-19)患者的临床和凝血功能特征。 方法: 回顾性分析2020年2月5日至2020年2月15日北京协和医院国家医疗队在武汉收治的7例危重型COVID-19患者临床及实验室资料。 结果: 7例患者中男性4例,女性3例,中位年龄59(49~71)岁,3例合并基础病。发热7例,干咳6例,呼吸困难4例,腹泻4例。所有患者均存在不同程度的肢端缺血,表现为肢端青斑或青紫、血疱、干性坏疽等。7例患者入住重症监护室时均存在D-二聚体显著升高、血小板计数正常,6例纤维蛋白原及纤维蛋白降解产物(FDP)升高,4例凝血酶原时间延长。随着病情进展,D-二聚体及FDP进行性升高,4例患者符合2017年中国弥散性血管内凝血诊断标准。6例患者接受低分子肝素治疗,治疗后D-二聚体及FDP下降,但临床症状无明显好转。中位随访26 d,5例患者死亡,从出现肢端缺血症状至死亡的中位时间为12(7~16)d。 结论: 部分危重型COVID-19患者存在明显高凝倾向,应关注此类患者凝血功能,及时识别高凝期并予抗凝治疗,肢端缺血提示预后不良。抗凝治疗能否改善预后仍需更多临床数据。.

Keywords: Anticoagulation therapy; COVID-2019; Critical; Hypercoagulation status.

PubMed Disclaimer

Figures

图1
图1. 例2双足缺血进行性加重,由足底青斑(A)发展为水疱(B)及肢端干性坏疽(C)
图2
图2. 例5(A、B)及例7(C、D)的肢端青紫及肢端坏疽

Comment in

References

    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J] Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7. - DOI - PMC - PubMed
    1. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J] J Thromb Haemost. 2020 doi: 10.1111/jth.14768. - DOI - PMC - PubMed
    1. 国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版)[Z] 2020年3月, 国卫办公函[2020]184号.
    1. 中华医学会血液学分会血栓与止血学组. 弥散性血管内凝血诊断中国专家共识(2017年版)[J] 中华血液学杂志. 2017;38(5):361–363. doi: 10.3760/cma.j.issn.0253-2727.2017.05.001. - DOI - PubMed
    1. Liu Jing, Li Sumeng, Liu Jia, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv. 2020 doi: 10.1101/2020.02.16.20023671. - DOI - PMC - PubMed

Substances